Exagen (NASDAQ:XGN – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02, Zacks reports. Exagen had a negative return on equity of 84.26% and a negative net margin of 30.36%. The company had revenue of $12.51 million for the quarter, compared to analyst estimates of $13.55 million. During the same period in the previous year, the firm earned ($0.31) earnings per share. Exagen updated its FY 2024 guidance to EPS.
Exagen Trading Up 1.4 %
NASDAQ:XGN traded up $0.04 on Wednesday, hitting $2.83. 12,373 shares of the company’s stock were exchanged, compared to its average volume of 41,816. Exagen has a 52 week low of $1.30 and a 52 week high of $3.71. The company has a current ratio of 4.32, a quick ratio of 4.32 and a debt-to-equity ratio of 1.13. The firm has a 50-day moving average price of $2.84 and a 200-day moving average price of $2.37.
Analyst Ratings Changes
Separately, William Blair reiterated an “outperform” rating on shares of Exagen in a research note on Wednesday.
Exagen Company Profile
Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
See Also
- Five stocks we like better than Exagen
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Rocket Lab is the Right Stock for the Right Time
- What Are the FAANG Stocks and Are They Good Investments?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- The Significance of Brokerage Rankings in Stock Selection
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.